RAY THERAPEUTICS, INC.

Adverum's Ixo-vec Shows Promise in Wet AMD Phase 2 Trial, Phase 3 Planned for 2025

7 months ago

• Adverum's Ixo-vec demonstrates maintenance of visual and anatomic outcomes in wet AMD patients, reducing the need for anti-VEGF injections. • The LUNA Phase 2 trial supports the selection of the 6E10 dose for Phase 3 pivotal trials, with the prophylactic regimen choice expected by year-end. • Adverum plans to initiate a Phase 3 clinical trial of Ixo-vec in wet AMD in the first half of 2025, pending additional funding. • Regulatory designations, including Fast Track and RMAT from the FDA, could accelerate Ixo-vec's development and review process.